Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 3,250 shares at $323.62 ($1.1M) on 2026-03-02, disclosed to the SEC on 2026-03-04.
Open-market sale of $1.1M ALNY by CSO & EVP, Head of Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $323.62 | 47 | $15K | 1.4% |
| 2 | $324.65 | 90 | $29K | 2.8% |
| 3 | $325.63 | 258 | $84K | 8.0% |
| 4 | $326.81 | 392 | $128K | 12.2% |
| 5 | $327.67 | 329 | $108K | 10.2% |
| 6 | $328.71 | 100 |
| $33K |
| 3.1% |
| 7 | $329.71 | 170 | $56K | 5.3% |
| 8 | $330.85 | 81 | $27K | 2.5% |
| 9 | $331.93 | 94 | $31K | 3.0% |
| 10 | $332.64 | 37 | $12K | 1.2% |
| 11 | $316.55 | 289 | $91K | 8.7% |
| 12 | $318.62 | 282 | $90K | 8.5% |
| 13 | $320.51 | 722 | $231K | 22.0% |
| 14 | $321.58 | 359 | $115K | 11.0% |
| Total | $323.62 avg | 3,250 | $1.1M | 100% |
| Filing → |
| ALNY | SELL | 2026-01-14 | $1.4M | — | Filing → |
| ALNY | SELL | 2025-11-19 | $7.1M | — | Filing → |
| ALNY | SELL | 2025-10-03 | $2.1M | — | Filing → |